StoxGranules India vs Cohance Lifesciences: share price & financials comparison
NSE: GRANULES vs COHANCE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Granules India vs Cohance Lifesciences at a glance
Granules India (GRANULES) has a market capitalisation of ₹22,182 Cr, against ₹17,546 Cr for Cohance Lifesciences (COHANCE). Over the past year Granules India has returned +43.2%, compared with -38.3% for Cohance Lifesciences. On valuation, Granules India trades at a lower P/E of 31.1 versus 370.4. Granules India earns a higher return on equity (10.9% vs 1.2%). Granules India comes out ahead on size, valuation, profitability, growth and momentum. Cohance Lifesciences comes out ahead on financial health and technicals. Across the scored metrics below, Granules India leads on 12 and Cohance Lifesciences on 4. On StoxGud's 10-point checklist, Granules India scores 8/10 and Cohance Lifesciences scores 5/10.
| Metric | Granules India | Cohance Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹22,182 Cr | ₹17,546 Cr |
| Revenue (latest FY) | ₹5,366 Cr | ₹2,269 Cr |
| Net profit (latest FY) | ₹595 Cr | ₹179 Cr |
| Valuation | ||
| P/E | 31.1 | 370.4 |
| P/B | 3.38 | 4.48 |
| Dividend yield | 0.16% | — |
| Profitability | ||
| Return on equity | 10.9% | 1.2% |
| Net profit margin | 12.1% | 2.3% |
| Operating margin | 22.7% | 11.2% |
| Growth | ||
| Revenue growth (YoY) | +20.3% | -14.2% |
| Net profit growth (YoY) | +39.2% | -79.5% |
| Revenue CAGR (multi-year) | +10.6% | +18.2% |
| Financial health | ||
| Debt to equity | 0.09 | 0.06 |
| Momentum | ||
| 1-month return | -0.2% | +4.9% |
| 1-year return | +43.2% | -38.3% |
| 3-year CAGR | +30.1% | -7.4% |
| 5-year CAGR | +21.9% | -2.3% |
| 10-year CAGR | +22.7% | — |
| Distance from 52W high | -10.6% | -36.6% |
| Technicals | ||
| RSI (14) | 55 | 53 |
| Price vs 200-day avg | +8.6% | +11.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Granules India | Cohance Lifesciences |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Granules India or Cohance Lifesciences?
Granules India has a market cap of ₹22,182 Cr and Cohance Lifesciences has a market cap of ₹17,546 Cr as of 13 Nov 2026.
Which has a lower P/E, Granules India or Cohance Lifesciences?
Granules India has the lower P/E: Granules India trades at 31.1 and Cohance Lifesciences at 370.4.
Which gave better returns in the last year, Granules India or Cohance Lifesciences?
Granules India did better: Granules India returned +43.2% and Cohance Lifesciences returned -38.3% over one year.
What is the difference between Granules India and Cohance Lifesciences?
Both are NSE-listed companies in Healthcare. Granules India is about 1.3 times the size of Cohance Lifesciences by market cap. In the latest financial year Granules India reported revenue of ₹5,366 Cr and Cohance Lifesciences ₹2,269 Cr. Operating margin is 22.7% for Granules India and 11.2% for Cohance Lifesciences. Debt to equity is 0.09 for Granules India and 0.06 for Cohance Lifesciences.
Which is better, Granules India or Cohance Lifesciences?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Granules India leads on 12 and Cohance Lifesciences on 4. Granules India is ahead on size, valuation, profitability, growth and momentum. Cohance Lifesciences is ahead on financial health and technicals. On StoxGud's rules-based checklist Granules India scores 8/10 and Cohance Lifesciences scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.